Outcome Objectives
1. Understand the history and pathophysiology of Meniere’s Disease (MD), medical
and surgical treatment options of MD, and non-destructive and destructive
treatment options of MD and when to recommend these.
2. Apply
appropriate diagnostic tests and AAO-HNSF criteria for diagnosis of MD.
3. Identify those patients at risk for
severe symptoms, including bilateral disease and predict and relate to
patients’ prognostic factors.
4. Develop a framework for patient,
family, and collegial education so that interested parties understand the
seriousness of MD.
Rex S. Haberman II, MD, faculty for this accredited education activity has no relevant financial relationships with ineligible companies to disclose.
Oliver F. Adunka, MD has the following relationships with ineligible companies to disclose: Consultant: MED-EL Corporation, Advanced Bionics Corporation, Spiral Therapeutics, AGTC Inc; Research support: MED-EL Corporation, Cochlear Corporation, Advanced Bionics Corporation; Ownership: Advanced Cochlear Diagnostics; Royalties: Advanced Bionics Corporation.
R. Mark Wiet, MD, faculty for this accredited education activity has no relevant financial relationships with ineligible companies to disclose.
Wade Chien, MD, faculty for this accredited education activity has no relevant financial relationships with ineligible companies to disclose.
David H. Jung, MD PhD, faculty for this accredited education activity has no relevant financial relationships with ineligible companies to disclose.
Planner
Christine Brown, CME planner and AAO-HNSF staff member has no relevant financial relationships with ineligible companies to disclose.
